Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the HD gene. Besides psychiatric, motor and cognitive symptoms, HD patients suffer from sleep disturbances. In order to screen a rat model transgenic for HD (tgHD rats) for sleep-wake cycle dysregulation, we monitored their circadian activity peaks in the present study. TgHD rats of both sexes showed hyperactivity during the dark cycle and more frequent light cycle activity peaks indicative for a disturbed sleep-wake cycle. Focusing on males at the age of 4 and 14 months, analyses of receptor levels in the hypothalamus and the basal forebrain revealed that 5-HT(2A)- and adrenergic alpha(2)-receptor densities in these regions were significantly altered in tgHD rats compared to their wild-type littermates. Adrenergic receptor densities correlated negatively with the light cycle hyperactivity peaks at later stages of the disease in male tgHD rats. Furthermore, reduced leptin levels, a feature associated with circadian misalignment, were present. Our study demonstrates that the male tgHD rat is a suitable model to investigate HD associated sleep alterations. Further studies are warranted to elucidate the role of adrenergic- and 5-HT(2A)-receptors as therapeutic targets for dysregulation of the circadian activity in HD.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbr.2009.06.031DOI Listing

Publication Analysis

Top Keywords

tghd rats
16
activity peaks
12
light cycle
12
adrenergic alpha2-receptor
8
huntington's disease
8
rat model
8
sleep-wake cycle
8
circadian activity
8
male tghd
8
cycle
6

Similar Publications

Mammalian transglutaminases (TGs) catalyze calcium-dependent irreversible posttranslational modifications of proteins and their enzymatic activities contribute to the pathogenesis of several human neurodegenerative diseases. Although different transglutaminases are found in many different tissues, the TG6 isoform is mostly expressed in the CNS. The present study was embarked on/undertaken to investigate expression, distribution and activity of transglutaminases in Huntington disease transgenic rodent models, with a focus on analyzing the involvement of TG6 in the age- and genotype-specific pathological features relating to disease progression in HD transgenic mice and a tgHD transgenic rat model using biochemical, histological and functional assays.

View Article and Find Full Text PDF

Hyperactivity of the dopaminergic pathway is thought to contribute to clinical symptoms in the early stages of Huntington's disease (HD). It is suggested to be result of a reduced dopaminergic inhibition by degeneration of medium spiny neurons in the striatum. Previously, we have shown that the number of dopaminergic cells is increased in the dorsal raphe nucleus (DRN) of HD patients and transgenic HD (tgHD) rats during the manifestation phase of the disease; as well as in the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) of tgHD rats.

View Article and Find Full Text PDF

Receptor for Advanced Glycation End Products (RAGE) is Expressed Predominantly in Medium Spiny Neurons of tgHD Rat Striatum.

Neuroscience

June 2018

Jan and Dan Duncan Neurological Research Institute, Texas Children Hospital, Department of Neuroscience, Baylor College of Medicine, 1250 Moursund St, Houston, TX 77030, United States. Electronic address:

Receptor for advanced glycation end products (RAGE) is a multi-ligand receptor involved in the pathology of several progressive neurodegenerative disorders including Huntington's disease (HD). We previously showed that the expression of RAGE and its colocalization with ligands were increased in the striatum of HD patients, increasing with grade severity, and that the pattern of RAGE expression coincided with the medio-lateral pattern of neurodegeneration. However, the exact role of RAGE in HD remains elusive.

View Article and Find Full Text PDF

The transgenic rat model of Huntington disease expressing a fragment of mutant HTT (tgHD rat) has been thoroughly characterized and reproduces hallmark symptoms of human adult-onset HD. Pursuing the optimization of this model for evaluation of translational therapeutic approaches, the F344 inbred rat strain was considered as advantageous genetic background for the expression of the HD transgenic construct. In the present study, a novel congenic line of the SPRDtgHD transgenic model of HD, carrying 51 CAG repeats, was generated on the F344 rat genetic background.

View Article and Find Full Text PDF

Impaired Decision Making and Loss of Inhibitory-Control in a Rat Model of Huntington Disease.

Front Behav Neurosci

October 2016

Institut des Neurosciences Paris-Saclay (Neuro-PSI), UMR 9197, Centre National de la Recherche Scientifique (CNRS) Université Paris Sud, Université Paris Saclay Orsay, France.

Article Synopsis
  • Cognitive deficits in Huntington disease (HD) primarily involve executive function issues like impulsivity and disinhibition, but research on behavioral disinhibition and decision-making related to HD is limited.
  • In a study using transgenic HD rats, various tasks demonstrated poor decision-making, impulsive behavior, and difficulty in waiting, indicating a significant presence of both cognitive and action impulsivity compared to normal rats.
  • The study found a dysfunctional amygdala in HD rats, with reduced volume and increased activity, suggesting it may contribute to their impulsivity, making tgHD rats a useful model for evaluating potential treatments for these symptoms.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!